HeartBeam Appoints Robert Eno as Chief Exec

HeartBeam has appointed Robert Eno as its new CEO, effective on October 21, 2024.
 
As part of this long-planned transition, founder and current CEO Branislav Vajdic, Ph.D. will transition into the role of president. Eno joined HeartBeam as president in January 2023 and will lead as the company works toward gaining the foundational U.S. Food and Drug Administration (FDA) 510(k) clearance for its vector-based technology.
 
As president, Dr. Vajdic will focus on further innovating the company’s vector-based technology, driving R&D efforts, and advancing artificial intelligence (AI) applications.
 
“HeartBeam is at an important inflection point and the transition comes at the right time where we can best leverage the unique strengths of each leader,” said Rich Ferrari, executive chairman of HeartBeam’s board of directors. “Branislav’s commitment to innovation and vision of providing unprecedented cardiac insights has enabled the Company to reach this pivotal point and we will continue to benefit from his drive to unlock the transformative opportunities ahead. Likewise, Rob has spent his career growing companies with innovative technologies, based on his keen understanding of sales, strategic marketing and go-to-market strategies, while maximizing value for stakeholders, and I am confident that his deep experience will ensure the company is well positioned for success.”
 
Eno has over 30 years of experience in the industry. He has created go-to-market strategies for multiple breakthrough products including noninvasive FFRCT for diagnosing coronary artery disease, laser cataract surgery, scanning retinal laser photocoagulation, and intravascular brachytherapy.
 
Before HeartBeam, Eno was CEO of Preview Medical, a company creating a new category of real-time, in vivo tissue classification for solid tumor cancers using machine learning and optical signals. He was previously senior VP of marketing for HeartFlow, leading marketing and product functions for a new category of personalized, non-invasive testing for heart disease.
 
Eno also had senior marketing and sales leadership positions at OptiMedica, NeoGuide Systems, and Avantec Vascular.
 
“The HeartBeam technology is truly transformative and stands to change how cardiac care is managed in the future. We’ve only scratched the surface of unlocking new insights and understanding how our data-rich signals can benefit physicians and patients,” said Eno. “I am honored to lead the company at this exciting time and look forward to my continued partnership with Branislav as we evolve our business and technology to deliver on strategic objectives.”
 
HeartBeam’s core vector-based technology captures the heart’s electrical signals from three dimensions to provide total heart intelligence. The company’s first application of the technology is a cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG. The HeartBeam system is currently under review with the FDA. The company has 13 issued U.S. patents and 4 issued international patents supporting the underlying technology.
 
Earlier this week, the company named Lance Myers, Ph.D. to the newly-created position of chief AI scientist. Last month, Timothy Cruickshank was named chief financial officer after the retirement of long-time HeartBeam CFO Richard Brounstein.